Ana Carolina Pavanelli
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Ana Carolina Pavanelli has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Flavia Regina Rotea Mangone
Centro de Investigação Translacional em Oncologia—CTO, Instituto do Câncer do Estado de Sao Paulo (ICESP), Faculdade de Medicina da Universidade de São Paulo (FMUSP), Avenida Doutor Arnaldo, 251, 8° Floor, Sao Paulo 01246-000, SP, Brazil
2 shared publications - Maria Aparecida Nagai
Instituto de Câncer de São Paulo, São Paulo, Brazil
2 shared publications Adriana Morgan
Departamento Patologia, Faculdade de Medicina da Universidade de São Paulo, Brazil
1 shared publication- Eliane Tigre Guimarães
Departamento Patologia, Faculdade de Medicina da Universidade de São Paulo, Brazil
1 shared publication - Fernanda Magalhães Arantes Costa
Department of Medicine, School of Medicine, University of São Paulo, São Paulo, Brazil
1 shared publication - Francine Maria Almeida
Laboratório de Terapêutica Experimental-LIM20, Faculdade de Medicina, Universidade São Paulo, São Paulo (SP), Brazil
1 shared publication
Latest Publications
- 1 November 2021
- Published by Elsevier in Toxicology
- Vol. 463, 152970
Effects of intrauterine exposure to concentrated ambient particles on allergic sensitization in juvenile mice
- 1 November 2021
- Published by Elsevier in Toxicology
- Vol. 463, 152970
Effects of intrauterine exposure to concentrated ambient particles on allergic sensitization in juvenile mice
- Open Access
Abnormal Long Non-Coding RNAs Expression Patterns Have the Potential Ability for Predicting Survival and Treatment Response in Breast Cancer
Abnormal long non-coding RNAs (lncRNAs) expression has been documented to have oncogene or tumor suppressor functions in the development and progression of cancer, emerging as promising independent biomarkers for molecular cancer stratification and patients’ prognosis. Examining the relationship between lncRNAs and the survival rates in malignancies creates new scenarios for precision medicine and targeted therapy. Breast cancer (BRCA) is a heterogeneous malignancy. Despite advances in its molecular classification, there are still gaps to explain in its multifaceted presentations and a substantial lack of biomarkers that can better predict patients’ prognosis in response to different therapeutic strategies. Here, we performed a re-analysis of gene expression data generated using cDNA microarrays in a previous study of our group, aiming to identify differentially expressed lncRNAs (DELncRNAs) with a potential predictive value for response to treatment with taxanes in breast cancer patients. Results revealed 157 DELncRNAs (90 up- and 67 down-regulated). We validated these new biomarkers as having prognostic and predictive value for breast cancer using in silico analysis in public databases. Data from TCGA showed that compared to normal tissue, MIAT was up-regulated, while KCNQ1OT1, LOC100270804, and FLJ10038 were down-regulated in breast tumor tissues. KCNQ1OT1, LOC100270804, and FLJ10038 median levels were found to be significantly higher in the luminal subtype. The ROC plotter platform results showed that reduced expression of these three DElncRNAs was associated with breast cancer patients who did not respond to taxane treatment. Kaplan–Meier survival analysis revealed that a lower expression of the selected lncRNAs was significantly associated with worse relapse-free survival (RFS) in breast cancer patients. Further validation of the expression of these DELncRNAs might be helpful to better tailor breast cancer prognosis and treatment.
Open AccessAbnormal Long Non-Coding RNAs Expression Patterns Have the Potential Ability for Predicting Survival and Treatment Response in Breast Cancer
Abnormal long non-coding RNAs (lncRNAs) expression has been documented to have oncogene or tumor suppressor functions in the development and progression of cancer, emerging as promising independent biomarkers for molecular cancer stratification and patients’ prognosis. Examining the relationship between lncRNAs and the survival rates in malignancies creates new scenarios for precision medicine and targeted therapy. Breast cancer (BRCA) is a heterogeneous malignancy. Despite advances in its molecular classification, there are still gaps to explain in its multifaceted presentations and a substantial lack of biomarkers that can better predict patients’ prognosis in response to different therapeutic strategies. Here, we performed a re-analysis of gene expression data generated using cDNA microarrays in a previous study of our group, aiming to identify differentially expressed lncRNAs (DELncRNAs) with a potential predictive value for response to treatment with taxanes in breast cancer patients. Results revealed 157 DELncRNAs (90 up- and 67 down-regulated). We validated these new biomarkers as having prognostic and predictive value for breast cancer using in silico analysis in public databases. Data from TCGA showed that compared to normal tissue, MIAT was up-regulated, while KCNQ1OT1, LOC100270804, and FLJ10038 were down-regulated in breast tumor tissues. KCNQ1OT1, LOC100270804, and FLJ10038 median levels were found to be significantly higher in the luminal subtype. The ROC plotter platform results showed that reduced expression of these three DElncRNAs was associated with breast cancer patients who did not respond to taxane treatment. Kaplan–Meier survival analysis revealed that a lower expression of the selected lncRNAs was significantly associated with worse relapse-free survival (RFS) in breast cancer patients. Further validation of the expression of these DELncRNAs might be helpful to better tailor breast cancer prognosis and treatment.